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Background: Uncontrolled blood pressure (BP) is a significant contributor of morbidity and even mortality in type
2 diabetes (T2D) patients. This study was done to determine the significant determinants of uncontrolled blood
pressure in T2D patients in Malaysia.
Methods: Between 1st January 2009 to 31st December 2009, data from 70 889 patients with Type 2 diabetes was
obtained from the Adult Diabetes Control and Management Registry for analysis; 303 centers participated in the
study. Their demographic characteristics, the nature of their diabetes, their state of hypertension, treatment
modalities, risk factors, and complications are described. Based on their most recent BP values, subjects were
divided into controlled BP and uncontrolled BP and their clinical determinants compared. Independent
determinants were identified using multivariate logistic regression.
Results: The mean age of patients at diagnosis of diabetes was 52.3 ± 11.1 years old. Most were women (59.0 %)
and of Malay ethnicity (61.9 %). The mean duration of diabetes was 5.9 ± 5.6 years. A total of 57.4 % were
hypertensive. Of the 56 503 blood pressure (BP) measured, 13 280 (23.5 %) patients had BP <130/80 mmHg.
Eighteen percent was on > two anti-hypertensive agents. Health clinics without doctor, older age (≥ 50 years old),
shorter duration of diabetes (< 5 years), Malay, overweight were determinants for uncontrolled blood pressure (BP
≥130/80 mmHg). Patients who were on anti-hypertensive agent/s were 2.7 times more likely to have BP ≥130/
80 mmHg. Type 2 diabetes patients who had ischaemic heart disease or nephropathy were about 20 % and 15 %
more likely to have their blood pressure treated to target respectively.
Conclusions: Major independent determinants of uncontrolled BP in our group of T2D patients were Malay
ethnicity, older age, recent diagnosis of diabetes, overweight and follow-up at health clinics without a doctor and
possibly the improper use of anti hypertensive agent. More effort, education and resources, especially in the
primary health care centres are needed to improve hypertensive care among our patients with diabetes.
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The profile of blood pressure (BP) management in Type 2
diabetes mellitus (T2D) patients has generally been unsat-
isfactory until about two decades ago [1,2]. In 1987, the
Hypertension in Diabetes Study (HDS) revealed that most
of the hypertensives went unrecognized, untreated and if
treated, the target blood pressure (BP) was unacceptably
high when compared to the current criteria [3]. The study
also revealed the benefits of lowering blood pressure in
these patients. It showed that the reduction of a mean
blood pressure of between 5 to 10 mmHg, reduced the
diabetes related deaths by one-third , the incidence of
stroke by almost half and reduced the incidence of heart
failure by almost one-third after a median follow-up
period of 8.4 years. Furthermore, detailed analysis showed
that the number needed to treat (NNT) to prevent one
major complication of diabetes was 6 patients and 15
patients for death [3]. These benefits also appeared more
favourable than those resulting from the intensified gly-
caemic control strategy for microvascular endpoints
(NNT 138 vs 357). Many other studies had showed similar
detrimental consequences of poor control of hypertension
in diabetics. A systematic review of observational studies
involving close to 48 000 patients showed that uncon-
trolled hypertension had a significant impact on diabetes-
related complications [4]. Also, of importance was
Framingham study which showed that while the risk of
death (7 %) and cardiovascular events (9 %) could be
attributed to diabetes, the risk of death and cardiovas-
cular events attributed to co-existent hypertension were
far higher; 44 % and 41 % respectively [5].
Patients with diabetes are especially vulnerable to
hypertensive injury. The coexistence of hypertension has
a significant impact of the poor prognosis for patients
with diabetes because of its effect on the micro and
macro vasculature. These include impaired autoregu-
lation of blood flow in the microcirculation, the
non-dipping of nocturnal BP owing to autonomic dys-
function, increased pulse-wave velocity and ventricular-
vascular mis-coupling from premature stiffening of the
abdominal aorta by elastic fibres glycation [6-9]. The
additional advantages of intensive and good BP control
for T2D patients are the increase of quality-adjusted
life-years (QALYs) and cost-effectiveness. This benefit
resulted from reduced cost of managing complications,
increased survival and an increase in the interval-free
complications [10,11]. Furthermore, the cost of man-
aging a T2D patient is not cheap. In Malaysia even in
the Public Health Service, the cost averaged around US
350 dollars a month if the patient saw a family physician
or US 250 dollars if he or she saw a non-specialist. If the
patient was admitted for treatment the cost doubled and
, if for complications e.g. stroke, foot gangrene, the cost
would escalate 10-fold [12].Clearly there is convincing evidence on the benefits of
effectively treating T2D patients who have hypertension.
However, we have no national data on this aspect of the
problem and neither do we know how effective we have
been in dealing with the problem. We therefore set out
to assess the care these patients have been given and in
particular, the variables that had a significant impact on
the uncontrolled blood pressure. We hoped that the
results will shed some light on the problem and guide
policy-makers in developing appropriate strategies for
prevention and for the proper allocation of health
resources to this area of diabetic management.
Methods
This was a cross-sectional study using data extracted
from the Adult Diabetes Control and Management
(ADCM) Registry in 2009. It represents 70 889 T2D
patients from 289 health clinics and 14 hospitals and
from 8 of the 15 states in the country and 2 Federal ter-
ritories. These represent 22.1 % of the health clinics and
9.6 % of the hospitals in the country. It has been esti-
mated that these patients represent 5.2 % of the total
number of diabetics in these areas (70889/1368590) [13].
Up to 31st December 2009, 3140 (4.4 %) were lost to
follow-up (defaulted appointment for > one year) and
203 (0.3 %) patients had passed on.
Only adult patients (≥18 years of age) were registered.
All patients were informed of the on-going registry and
given the opportunity to opt out. However, the participa-
tion in ADCM was non-mandatory for patients and
health centres. Data collection at local centers was per-
formed by trained physicians, assistant physicians and
nurses. All data on the participating patients were regis-
tered on an on-line standard case record form (CRF)
and the information was made available in the ADCM
website. This website was maintained by Clinical Re-
search Centre (CRC), Ministry of Health, Malaysia.
The Malaysian health care system for patients with
diabetes
The health care system in Malaysia is supported by the
public and the private sectors [14]. The private health
care provides about two thirds of the country’s medical
specialists and caters for about one third of the upper-
middle income groups of the population [15]. The public
health care is organized by Ministry of Health and struc-
tured into the public health clinics and hospital care.
The health clinics are well-linked to the secondary and
tertiary public hospitals with its unique referral system.
The patients in health clinics generally are managed by
family medicine specialists (FMS), medical and health
officer (M&HO), physician assistant and supported by
specialized nurses and dietitians/nutritionists. In hospi-
tals, care is provided by specialists in internal medicine
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nurses. Under the system, every patient diagnosed with
diabetes mellitus will receive a green booklet which will
be kept by the patient. This is accompanied with a big-
ger green medical record book (kept at the health
centre) that records all information pertaining to the
care provided for the patient’s management. Those
patients managed in the health clinics and who have
complications are referred to the hospitals either for ad-
mission or for a co-shared care as outpatients. In health
clinic without a FMS/M&HO, the cases are normally
managed by physician assistants. Nurses at these health
clinics contributed in measuring clinical parameters dur-
ing patients’ visit and giving health education at the ap-
pointment day. Another reason for this referral is for the
prescription of more expensive anti-diabetic agents
(ADA), lipid-lowering agents or the newer or more ex-
pensive anti-hypertensive drugs. These are restricted
items and can only be dispensed at the hospitals [16].
All major classes of anti-hypertensive drugs (including
renin inhibitors, angiotensin receptor blockers, calcium
channel blockers) are available in the public health sec-
tor. The newer, original and more expensive drugs are
restricted and those that of older and generic are com-
monly used in patient care in compliance to the national
clinical practice guideline.
Definitions of study participants
A person was considered to have T2D if there was docu-
mented evidence of a diagnosis of diabetes mellitus
(WHO criteria) and who was being treated either by life-
style modification, oral ADA or insulin. Hypertension was
diagnosed if the systolic blood pressure was ≥130 mm Hg
or the diastolic blood pressure was≥ 80 mm Hg on each
of two successive readings measured in rested position
with arm at heart level using a cuff of appropriate size; a
BP< 130/80 mmHg was regarded as well controlled. Body
mass index (BMI) was calculated as weight (kilogram)
divided by height (metre) squared and categorized into
underweight (<18.5), normal (18.5-22.9) and overweight
(≥23.0); for the category of obesity it was further classified
into pre-obese (23.0-27.4), obese I (27.5-34.9), obese II
(35.0-39.9) and obese III (≥ 40). For their lipid profiles, a
low density lipoprotein-cholesterol (LDL-C)≤ 2.6 mmol/L,
triglyceride (TG)≤ 1.7 mmol/L and high density
lipoprotein-cholesterol (HDL-C)≥ 1.1 mmol/L were
regarded as good treatment targets [17].
A diagnosis of cerebrovascular disease/stroke (CVD),
ischemic heart disease (IHD), retinopathy, nephropathy
and foot problem were based on symptoms, signs, la-
boratory results, radiological evidence and treatment his-
tory. Nephropathy was diagnosed by the presence on ≥ 2
occasions and at least three months apart of any of the
following: microalbuminuria, proteinuria, serumcreatinine > 150 mmol/L or estimated glomerular filtra-
tion rate < 60mls/min (Cockroft-Gault formula). Foot
problems were defined as any deformity resulted from
ulcers, amputation, peripheral neuropathy or peripheral
vascular disease.
Statistical analysis
The independent variables of interest were the types of
clinic and how it was manned, gender, ethnicity, age, dur-
ation of diabetes, body mass index (BMI), waist circumfer-
ence, CVD, IHD, retinopathy, nephropathy, erectile
dysfunction (ED), diabetic foot problems, anti-
hypertensive treatment, glycaemic control [HbA1c≤ 6.5 %
(48 mmol/mol)] and lipid profile control (LDL-
C≤ 2.6 mmol/L, TG≤ 1.7 mmol/L, HDL-C≥ 1.1 mmol/L).
Mean levels were compared using the Student’s t test
for unpaired samples and proportions compared with
Chi square test. The normality of each variable was first
tested by histogram and confirmed by Kolmogorov-
Smirnov test. A two-tailed P value of < 0.05 was consi-
dered to be significant.
Having grouped the patients into controlled and un-
controlled BP using the latest mean BP values, logistic
regression was used to determine the significant clinical
determinants. The significant determinants were then
identified and fitted into a multivariate logistic regres-
sion model using the stepwise method with uncontrolled
BP as the dependent variable. Multicolinearity between
the variables were checked with correlation matrix and
inspected for the magnitude of the standard error (SE).
None of the variables correlated with each other, r < 0.2
and SEs were all within 0.001 to 5.0. All data was ana-
lysed using STATA version 9.
Results
Of the 70 889 patients with T2D analysed, most were
women (59.0 %) and Malays 62 %) (Table 1). The mean
age at diagnosis of diabetes was 52.3 ± 11.1 years and the
mean duration of diabetes was 5.9 ± 5.6 years. The mean
systolic and diastolic blood pressures (BP) were
136.7 ± 19.5 mmHg (95 % CI ,136.6 to 136.9) and
78.8 ± 10.6 mmHg (95%CI , 78.7 to 78.9) respectively. A
total of 40 659 (57.4 %) patients were reported to be
hypertensive. Of the 56 503 BP measurements recorded
from these patients, 33.8 % had systolic BP < 130 mmHg,
44.8 % had diastolic BP < 80 mmHg and 23.5 % patients
had BP <130/80 mmHg. A more detailed report on this
has been published elsewhere [13].
The variables that determined good control of BP on
univariate analysis were, the type of health clinic, ethni-
city, age group, duration of diabetes, BMI, HbA1c, tar-
gets of lipid profiles and use of anti-hypertensive agent
(Table 1; Figure 1) Although insulin use was associated
with blood pressures being controlled to target
Table 1 Association of registered variables with blood pressure controlled to target, n = 56503{
Variable Total n (% of total) Controlled BP n (%) Uncontrolled BP n (%) Test statistic value, p-value
Total 56503 (100) 13280 (23.5) 43223 (76.5) NA
Type of Health Clinic, n = 53941
Without FMS/doctor 12009 (22.3) 2558 (21.3) 9451 (78.7) 48.81, < 0.001*
With FMS/doctor 41932 (77.7) 10221 (24.4) 31711 (75.6)
Gender 2.66, 0.27*
Male 22548 (39.9) 5326 (23.6) 17222 (76.4)
Female 33866 (59.9) 7927 (23.4) 25939 (76.6)
Missing 89 (0.2) 27 (30.3) 62 (69.7)
Ethnicity 344.98, <0.001*
Malay 35181 (62.3) 7484 (21.3) 27697 (78.7)
Chinese 11051 (19.6) 2761 (25.0) 8290 (75.0)
Indian 9627 (17.0) 2891 (30.0) 6736 (70.0)
Others 558 (1.0) 119 (21.3) 439 (78.7)
Missing 86 (0.2) 25 (29.1) 61 (70.9)
Age group (year)
Mean (SD) (58.32, 11.27) (57.21, 11.43) (58.38, 10.86) 10.717, <0.001#
<30 445 (0.8) 147 (33.0) 298 (67.0) 143.83, <0.001*
30-49 11452 (20.3) 3128 (27.3) 8324 (72.7)
50-69 35877 (63.5) 8029 (22.4) 27848 (77.6)
> = 70 8729 (15.4) 1976 (22.6) 6753 (77.4)
Duration of diabetes (year)
Mean (SD) (5.86, 5.56) (5.99, 5.59) (5.75, 5.47) 4.457, <0.001#
<5 28704 (50.8) 6555 (22.8) 22149 (77.2) 17.29, 0.001*
5-10 19528 (34.6) 4677 (23.9) 14851 (76.1)
>10 7962 (14.1) 1979 (24.8) 5983 (75.2)
Missing 309 (0.5) 69 (22.3) 240 (77.7)
BMI (kg/m2) 53687 (100) 12677 (23.6) 41010 (76.4)
Mean (SD) (27.28,5.96) (26.46, 5.16) (27.53, 6.16) 17.72, <0.001#
Underweight < 18.5 890 (1.7) 317 (35.6) 573 (64.4) 250.44, <0.001*
Normal 18.5-22.9 8792 (16.4) 2544 (28.9) 6248 (71.1)
Overweight≥ 23.0 44005 (77.9) 9816 (22.3) 34189 (77.7)
Pre-obese 23.0-27.4 20868 (38.9) 5118 (24.5) 15750 (75.5) 148.07, <0.001*
Obese I 27.5-34.9 19343 (36.0) 4065 (21.0) 15278 (79.0)
Obese II 35.0-39.9 2815 (5.2) 478 (17.0) 2337 (83.0)
Obese III≥ 40 979 (1.8) 155 (15.8) 824 (84.2)
HbA1c≤ 6.5 % (48 mmol/mol) 26052 (46.1) 6228 (23.9) 19824 (76.1) 0.04
> 6.5 % (48 mmol/mol) 30451 (53.9) 7052 (23.2) 23399 (76.8)
LDL-C≤ 2.6 mmol/L 11990 (21.2) 3016 (25.2) 8974 (74.8) <0.001
> 2.6 mmol/L 44513 (78.8) 10264 (23.1) 34249 (76.9)
TG, n = 44121 <0.001
≤ 1.7 mmol/L 23867 (54.1) 6018 (25.2) 17849 (74.8)
> 1.7 mmol/L 20254 (45.9) 4412 (21.8) 15842 (78.2)
HDL-C≥ 1.1 mmol/L 43986 (77.8) 10235 (23.3) 33751 (76.7) 0.01
> 1.1 mmol/L 12517 (22.2) 3045 (24.3) 9472 (75.7)
A BP< 130/80 mmHg was regarded as controlled BP.
NA =not applicable.
Missing rows represent either missing value of the variable or BP measurement, { the total used as the denominator in the total column, the different total is
otherwise stated in the sub-headings, *Chi-square test on category variables, and #t-test on continues variables (not including missing).
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Table 2 Multivariate logistic regression used stepwise
method conducted for uncontrolled hypertension,
n = 43223
Independent variables: OR 95 % CI P value
Type of Health Clinic
Without FMS/doctor 1.11 1.04, 1.18 0.002
With FMS/doctor 1 - -
Age (years)
< 30 1 - -
30-49 1.18 0.89, 1.56 0.24
50-69 1.30 0.99, 1.72 0.06
≥ 70 1.28 0.96, 1.71 0.09
Ethnicity
Malay 1.41 1.30, 1.52 <0.001
Chinese 1.19 1.09, 1.31 <0.001
Indian 1 - -
Duration of diabetes (years)
< 5 1.12 1.02, 1.22 0.01
5-9 0.96 0.87, 1.05 0.33
≥ 10 1 - -
BMI (kg/m2)
< 23 1 - -
≥ 23 1.35 1.26, 1.44 <0.001
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ADA, diet therapy and HbA1c levels.
Of interest was that those who were being treated for
hypertension did not have their blood pressure control
on target (Figure 1) This was irrespective of whether
they were on single (80.1 % vs 74.7 %, χ 2 = 204.66,
p < 0.001), double (82.6 % vs 74.6 %, χ 2 = 371.69,
p < 0.001) or ≥ triple anti-hypertensive agents (82.7 % vs
75.5 %, χ 2 = 186.98, p < 0.001).
Of the 41 286 (58.2 %) patients on anti-hypertensive
agents, angiotensin-converting enzyme inhibitors (ACEI)
(63.9 %) were the most prescribed, followed by calcium
channel blockers (CCB) (37 %) beta-blockers (36.5 %) and
diuretics (23.4 %). The use of specific anti-hypertensive
drug classes had been assessed and reported elsewhere [13].
Health clinics without a doctor, older age (≥ 50 years
old), shorter duration of diabetes (< 5 years), non-Indians
(being Malay), overweight, being on anti-hypertensive
agents and having poor lipid profile (LDL-C> 2.6
mmom/L) were predictors for uncontrolled blood pres-
sure (BP ≥130/80 mmHg). Patients who were on anti-
hypertensive agent/s were 2.7 times more likely to have
uncontrolled BP. T2D patients who had IHD or nephro-
pathy were about 20 % and 15 % more likely to have their
blood pressure treated to target, respectively (Table 2).Anti-Hypertensive Agent
On Anti-Hypertensive/s 1 - -
No Anti-Hypertensive 0.37 0.34, 0.39 <0.001
Ischaemic Heart Disease
Absent 1 - -
Present 0.84 0.72, 0.97 0.02
Nephropathy
Absent 1 - -
Present 0.87 0.78, 0.97 0.01
LDL> 2.6 mmol/L 1.13 1.06, 1.21 <0.001Discussion
We set out to examine the status of our T2D patients
with hypertension. The results were sub-optimal; less
than one in four patients had their BPs controlled to the
recommended target. This is despite convincing evi-
dence that aggressive lowering of BP in people with dia-
betes reduces cardiovascular morbidity and mortality
[18] Furthermore, the poor control persisted despite the
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Figure 1 Proportion of Type 2 Diabetes Patients Based on the
Number of Blood Pressure Measurements (N = 56503) and
Proportion of Blood Pressure Target Achieved According to the
Number of Anti-hypertensive Agents. A BP< 130/80 mmHg was
regarded as controlled BP.
≤ 2.6 mmol/L 1 - -
CI = confidence interval; OR = odds ratio.than two antihypertensive agents. Others have had a
similar experience [4,19-22].
Our findings suggested that treating BP to target was
associated with less proportion of lipid profiles and
HbA1c not at treatment targets (20-25 %). It was not the
case in reverse when treating these lipid profiles and
HbA1c to targets, we noticed that a large proportion of
T2D patients were still not at BP target (about 75 %).
Therefore, simultaneous management of all these risk
factors is most cost-effective via BP lowering effort.
Sever P et al reported a potential synergy between the
use of amlodipine-based blood pressure lowering agent
and lipid lowering agent (atorvastatin 10 mg) in the
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
which comprised 10 305 patients with about a quarter of
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reduction in the relative risk of coronary heart disease
when patients received both these agents compared to
using only statins (36 %). Perhaps, as has been con-
firmed by other studies, such combinations should be
started early in our patients in order to achieve max-
imum benefit [24,25].
Of the demographic characteristics, we found that
those who were > 50 years old, recently diagnosed with
diabetes, overweight (and obese) and of Malay ethnicity
were more likely to have uncontrolled BP and require
closer monitoring. The high proportion of Malays was
probably a reflection of the population distribution in
Malaysia with Malays being the dominant race. It has
been shown that a combination of T2D, resistant hyper-
tension and obesity was related to autonomic imbalance
(heart rate variability) and circadian disruption of the
sympathetic and parasympathetic tones during day and
night periods. These effects may contribute to the
observed increased risk of cardiovascular morbidity and
mortality [26]. Preventive measures should therefore
concentrate on these patients. In our experience, gender
was not an independent risk factor for uncontrolled BP.
The Western experience was different. In Sweden, fe-
male patients with diabetes were found to exhibit more
uncontrolled hypertension [27]. The Mayo clinic experi-
ence in the USA showed that in their group of 1090 dia-
betic patients with hypertension, older female, with
isolated systolic hypertension and with uncontrolled BP
at baseline were predictors of uncontrolled BP (≥ 130/
85 mmHg) [28]. Our patients who had either nephropa-
thy or IHD had better control of their blood pressures.
The experience in MAYO clinic was similar [28]. The
most probable reason was that these patients were under
the care of specialists and in the hospitals. However, the
Swedish experience was different; despite more than
94 % of them being on anti-hypertensives, good control
of blood pressure was achieved in only 60 % of these
patients [29].
The way in which our patients were being treated with
hypertensive agents appears to be less than satisfactory.
More than half of the patients were on two or more
drugs and despite this; good control has not been
achieved. Granted that most patients with T2D diabetes
may require combination therapy [30] but the proper
combination is important. The combination of a renin-
angiotensin-aldosterone system (RAAS) inhibitors and a
CCB has been shown to be an effective combination
[31,32].
Therefore the education of the physicians managing
these patients, the use of proper combinations, attending
to the individual needs of the patient and adherence to
guidelines are ways in which this area can be improved
[33]. Thus, training program in this aspect of prescribingfor diabetic hypertensive is ever more needed for the
majority non-specialist primary care physicians. Pertin-
ent aspects of drugs prescription should include safety
issues such as monitoring of renal function post-
initiation of a RAAS inhibitor, not over-aggressive in
treating systolic BP (< 120 mmHg) in T2D patients who
are at high risk for CVD events [34]. Patient-centred
consultation strategies to enhance patient participation
in decision making and to empower patient on hyper-
tension self-management that would improve therapy
adherence [35]. Besides, the clinicians should be encour-
aged out of inertia and taught on adding the third and
more anti-hypertensive agents judiciously because some
over-weighing the risk of polypharmacy against the opti-
mal BP control [36]. The limited availability of certain
anti-hypertensive agents such as the long-acting CCB
and ARB could be the underlying cause of the majority
patients under non-specialist primary care physician care
did not achieve target BP level.
Not surprisingly, BP control among the T2D patients
was better at the health clinics where a doctor was
present when compared to those without. Rohana D
et al has shown convincing evidence that in Malaysia,
where the clinics were manned by a M&HO or family
physician, the care was significantly better [37]. The
solution therefore is to man more clinics with doctors
or if that is not possible, have in place a proper and
appropriate referral system for those patients whose
hypertension prove difficult to control. An alternative
is to transfer these patients to a neighbouring general
practice clinic but the organization and logistics of
doing so can be difficult [38].
There may be other factors that may have contributed
to the poor control of hypertension. Concentration on
the glycaemic control (HbA1c) at the expense of the
hypertension could be one factor [39,40]. Inadequate
training for our physicians on the principles of evidence
based guidelines and health system that support these
guidelines adherence may be another [41-43]. Failure to
individualise treatment according to the needs of the pa-
tient and the lack of a team approach involving nurses,
medical assistants, pharmacists, nutritionists/dietitians
may be another factor [40,44,45]. Providing guidelines,
having appropriate protocols and knowledge instruments
that has been validated for use in this country should be
put in place and then, perhaps the medical care for dia-
betic hypertensive would improve [42,46].
The limitations of our study are recognized. The sam-
ple studied may not have been representative of the
country. Not all hospitals or health clinics were involved
in the survey. Furthermore, 20 % of the blood pressure
recordings were missing [47]. A large proportion of dia-
betic patients are being managed in the private sector
and the situation with regards to control of blood
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may affect the results such as the socioeconomic status,
health literacy, professional support, mental disorders,
smoking, physical activity, alcohol consumption, medica-
tion adherence etc. were not considered in our study
[48,49]. Notwithstanding these deficiencies, we feel that
a large sample size of 70,000 patients and from their
demographic characteristics may actually be representa-
tive of patients with T2D seeking treatment in the Public
Health Centres.Conclusions
T2D patients who were older, recently diagnosed, obese
and having care at a health clinic without a doctor were
more likely to have uncontrolled BP. These patients can
be clearly identified and therefore preventive measures
should concentrate on this group of patients. The inappro-
priate use of anti-hypertensive agent may be another iden-
tifiable reason for the poor control of hypertension.
Investment in these areas in terms of appointment of
trained physicians to health clinics and drawing up proper
guidelines in their management of hypertension, especially
in improving physician prescribing capability, should be a
priority in order to reduce the unfavourable consequences
of hypertension in our patients with T2D.
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